Business
DICOT: Phase 2a study enrollment completed; strong cash position supports next development steps
DICOT: Phase 2a study enrollment completed; strong cash position supports next development steps
About this update from Dicot Pharma Ab
Phase 2a study for LIB-01 completed enrollment, with results expected by November 2025. Net loss widened due to increased clinical activity, but cash reserves remain strong after a successful warrant exercise.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.